VERNON HILLS, Ill., March 17 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that an agreement has been signed with Cambrex Charles City, Inc., a subsidiary of Cambrex Corporation , a leading provider to the pharmaceutical industry, to develop an enhanced process for manufacturing DB289. This formulation is Immtech's first oral drug currently in Phase II human clinical trials for the treatment of malaria, Pneumocystis carinii pneumonia and African sleeping sickness.
Immtech selected Cambrex for its expertise in developing novel chemical synthesis methods and capabilities to manufacture drug products in small and large scale. Upon development of the synthesis method for DB289, Cambrex Charles City, Inc. is expected to manufacture the drug substance in bulk.
T. Stephen Thompson, President and CEO of Immtech, stated, "Cambrex brings a wealth of experience in process development and large-scale commercial manufacturing which we believe is important to further advance our drug DB289 from clinical trials to commercialization."
Gary Mossman, President & CEO, Cambrex Pharma and Biopharmaceuticals Business Unit, stated, "Cambrex is very excited about the new contract with Immtech. This agreement demonstrates the strength of Cambrex's embedded proprietary technologies, our capabilities to manufacture at clinical through commercial scales, and our dedication to bringing quality and value to our clients."
About Immtech International
Immtech International Inc. is pharmaceutical company focused on the commercialization of oral treatments for infectious diseases such as pneumonia, fungal infections, malaria, tuberculosis, hepatitis and tropical diseases such as African sleeping sickness and Leishmaniasis. The Company has worldwide exclusive rights to commercialize a dicationic pharmaceutical platform from which a pipeline of products may be developed to target large, global markets. For further information, please visit Immtech's website http://www.immtech.biz/ or call F. C. Thompson (877-898-8038).
Cambrex is a global, diversified life sciences company dedicated to providing innovative products and services to accelerate drug discovery, development, and the manufacture of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit Cambrex's website at http://www.cambrex.com/.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release regarding Immtech International, Inc.'s business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K/A as amended, for the most recently ended fiscal year and subsequent quarterly reports on Form 10-Q.
CONTACT: F. C. Thompson: 877-898-8038
Immtech International, Inc.